Novartis Files For Approval Of Rasilez In Japan
This article was originally published in PharmAsia News
Novartis Pharma of Japan has applied for approval of the high blood pressure drug Rasilez (aliskiren). Aliskiren is the first in a new class of medicine that works by inhibiting renin (an enzyme secreted by the kidney). Aliskirenhas been approved by the U.S. FDA and is sold under the name Tektuna in the U.S. and as Rasilez in Europe. (Click here for more - Japanese language
You may also be interested in...
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.
Market Intel: Why Telehealth, Digital Therapies Will Provide Mental Health Support Beyond COVID-19 Crisis
In this second part of a two-part series focusing on mental health tech, Medtech Insight highlights behavioral digital health companies that have attracted investors’ attention. Part one focused on transcranial magnetic stimulation.